Molecular network analysis of signaling pathways in metastatic breast cancer in patients treated with erlotinib.

被引：0
|
作者：
Speer, R.
Wallwiener, D.
Yang, S. X.
Swain, S. M.
Wulfkuhle, J. D.
Liotta, L. A.
Petricoin, E. F.
机构：
[1] Univ Tubingen, Tubingen, Germany
[2] NCI, Bethesda, MD 20892 USA
[3] George Mason Univ, Manassas, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10064
引用
收藏
页码：556S / 556S
页数：1
相关论文
共 50 条
  • [1] Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib.
    Oza, AM
    Townsley, CA
    Pond, G
    Singh, S
    Siu, LL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 865S - 865S
  • [2] Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib.
    Pao, W.
    Balak, M. N.
    Riely, G. J.
    Li, A. R.
    Zakowski, M. F.
    Ladanyi, M.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 383S - 383S
  • [3] Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
    Layman, Rachel M.
    Ruppert, Amy S.
    Lynn, Melinda
    Mrozek, Ewa
    Ramaswamy, Bhuvaneswari
    Lustberg, Maryam B.
    Wesolowski, Robert
    Ottman, Susan
    Carothers, Sarah
    Bingman, Anissa
    Reinbolt, Raquel
    Kraut, Eric H.
    Shapiro, Charles L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1183 - 1190
  • [4] Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
    Rachel M. Layman
    Amy S. Ruppert
    Melinda Lynn
    Ewa Mrozek
    Bhuvaneswari Ramaswamy
    Maryam B. Lustberg
    Robert Wesolowski
    Susan Ottman
    Sarah Carothers
    Anissa Bingman
    Raquel Reinbolt
    Eric H. Kraut
    Charles L. Shapiro
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1183 - 1190
  • [5] Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer
    Layman, Rachel M.
    Ruppert, Amy S.
    Lynn, Melinda
    Mrozek, Ewa
    Ramaswamy, Bhuvaneswari
    Lustberg, Maryam B.
    Susan, Ottman
    Carothers, Sarah
    Kraut, Eric H.
    Shapiro, Charles L.
    BLOOD, 2010, 116 (21) : 726 - 727
  • [6] FDG-PET and CT as early predictors of outcome in NSCLC patients treated with erlotinib.
    Iannone, Robert
    Evelhoch, Jeffrey L.
    Lam, Raymond
    Bergstrom, Donald Alan
    Thornton, Bob
    Herman, Gary A.
    Mozley, P. David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Targeting the Twist and Wnt signaling pathways in metastatic breast cancer
    Glackin, Carlotta A.
    MATURITAS, 2014, 79 (01) : 48 - 51
  • [8] Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
    Maura N. Dickler
    Melody A. Cobleigh
    Kathy D. Miller
    Pamela M. Klein
    Eric P. Winer
    Breast Cancer Research and Treatment, 2009, 115 : 115 - 121
  • [9] Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
    Dickler, Maura N.
    Cobleigh, Melody A.
    Miller, Kathy D.
    Klein, Pamela M.
    Winer, Eric P.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (01) : 115 - 121
  • [10] Analysis of signaling pathways in recurrent breast cancer
    Wu, J. Z.
    Yang, T. J.
    Lu, P.
    Ma, W.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (04): : 10097 - 10104
12345